IPF-021

Idiopathic Pulmonary Fibrosis (IPF)

London 74 years old male United Kingdom Total Cost: 155

Patient Condition

The patient was presented with progressive dyspnea worsening for 2 years and had a history of smoking (40 pack-years). HRCT showed extensive honeycomb lung and lattice shadows. Lung function: FVC 48% predicted, DLCO 30% predicted. 6MWD 250m, mMRC score 4. Complicated with pulmonary hypertension (mPAP 35mmHg). Advanced IPF was diagnosed.

Treatment Timeline

PhaseDetailsDate
integrated assessment
treatment initiation
Combination therapy (Months 1-12)
Maintenance treatment (Months 13-24)

Treatment Outcome

beforeFVC accounted for 48% of predicted value, DLCO accounted for 30% of predicted value, 6MWD 250m, mMRC score 4, combined with pulmonary hypertension (mPAP 35mmHg)
afterAfter 24 months of treatment, FVC accounted for 43% of the predicted value (annual decline rate was approximately 2.5%), DLCO accounted for 25% of the predicted value, 6MWD was 255m, and mMRC score was 4. Improved pulmonary hypertension
highlightIn patients with advanced IPF combined with pulmonary arterial hypertension, Nintedanib combined with ambrisentan can effectively delay disease progression and significantly reduce pulmonary arterial pressure.

Similar Cases

Related Recommendations